The case highlights the abuses of certain practices at the border of care and commerce, and recalls the importance of scientific and regulatory control in the field of innovative therapies.
Behind the promise of healing, a technique never validated
For several months, the company Linden Clinics, based in Türkiye, has been boasting on its site a “stem cell and exosome therapy“supposed to treat”autism, cerebral palsy, diabetes, multiple sclerosis, developmental delays, heart treatment as well as amyotrophic lateral sclerosis (ALS) or neurodegenerative diseases (MND) in general“.
The ANSM recalled that this treatment “meets the definition of drug“but that he”has not been the subject of a marketing authorization (AMM) in France or in Europe“. She emphasizes that “no robust data to date attest to the effectiveness, safety or quality of this treatment“.
These details are crucial: in the absence of validated clinical trials, the effectiveness of this type of therapy remains unknown. However, the patients concerned are often families faced with serious illnesses, sometimes without curative treatment.
A health policy decision to protect patients
On October 17, 2025, the ANSM made public a firm measure: the suspension of advertising broadcast by Linden Clinics on French territory. She indicates having taken “a health police decision against the company Linden Clinics“, considering that the promotional messages “concerned an unauthorized medicinal product“.
The agency specifies: “A treatment that does not have a Marketing Authorization may present health risks and constitute a loss of opportunity for the patient who would forgo validated treatments in this context.“.
This decision is part of the ANSM’s mission: to ensure the health safety of patients and the regulation of commercial practices around medicines and therapeutic products.
If you have used this therapy, the steps to follow
The ANSM explicitly recommends:Do not use stem cell and exosome treatment promoted by Linden Clinic as its effectiveness and safety have not been demonstrated.“.
She invites people who have used this therapy to consult their healthcare professional and “detail the treatments you are taking and the procedures that have been performed or proposed as part of treatment with stem cells and exosomes“.
The agency also asks that any adverse effects related to this therapy be reported via available pharmacovigilance channels.
By recalling the strict framework of cell therapies, this decision aims to protect patients sometimes in desperate search of solutions. She reminds us that in medicine, prudence remains an essential condition for hope.
When a legitimate desire for healing meets a vague framework, the role of authorities becomes vital to ensure that the step towards innovation does not become a leap into uncertainty.